Guggenheim maintains Buy on ArriVent BioPharma, $18 target
Guggenheim kept a Buy rating on ArriVent BioPharma and maintained a $18.00 price target.
Story updates
01:09:05 PM UTC
SquawkNews
Ratings actions from Benzinga
Guggenheim kept a Buy rating on ArriVent BioPharma and maintained a $18.00 price target.